Biotech

Blueprint Medicines Provides 2023 Portfolio Goals to Achieve Precision at Scale PR Newswire — Expect to achieve high-end of 2022 total revenue guidance of $180 million to $200 million and AYVAKIT product revenue guidance of more...

Fate Therapeutics FATE shares ended the last trading session 9.3% higher at $11.12. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the more...

BrainStorm Cell Therapeutics to Present at Biotech Showcase™ 2023 PR Newswire NEW YORK , Jan. 5, 2023 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, more...

WALTHAM, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that leading retina specialist Caroline Baumal, M.D., has joined Apellis as chief more...

JERUSALEM, Jan. 05, 2023 (GLOBE NEWSWIRE) — via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) , a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and more...

Monthly information regarding the total number of voting rights and total number of shares of the Company as of Dec em ber 3 1 , 202 2 (Article 223-16 of the General Regulations of the more...

Strong Cash Position with Runway into Fourth Quarter 2024 Non-Clinical Data on Immunosuppression Regimen Supportive of Clinical Programs Preclinical Data from HMI-103 Gene Editing Program Utilizing a Unique Mechanism of Action Demonstrated Significantly Increased Potency more...

– Topline results from ENLIVEN Phase 2b NASH trial on track for first quarter of 2023 – – Feedback from FDA supports advancement of Phase 3 program for pegozafermin in SHTG; plan to initiate first more...

Vera Therapeutics, Inc. VERA announced positive top-line data from the phase IIb ORIGIN study evaluating its lead product candidate, atacicept, for treating patients with immunoglobulin A nephropathy (IgAN). The double-blind, placebo-controlled ORIGIN study evaluated the more...

Deciphera Pharmaceuticals, Inc. DCPH announced an outlook and planned corporate milestones for 2023. The company outlined certain commercial, clinical and preclinical activities for the year. Along with the same press release, DCPH announced preliminary revenues more...